NCT03268668 Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis
| NCT ID | NCT03268668 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Condition | Stroke, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2017-07-13 |
| Primary Completion | 2027-07-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2017-07-13 with a primary completion date of 2027-07-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the cases, the thrombectomy procedure makes it possible to retrieve either partially or completely the clot. Previous studies have analyzed the correlation between the composition of the thrombus and the etiology of stroke. Their discordant results do not yet make it possible to distinguish a particular profile of thrombus according to etiology. Other studies have shown a correlation between the proportion of red blood cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning. More recently, one study has demonstrated a correlation between the presence of lymphocytes in the thrombus and an atheromatous etiology. The main limitations of these studies are the small number of patients included, the high variability of conservation protocols and the absence of plasma data, which does not allow for research on the correlation between clot composition and plasma biomarkers.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and older * Presenting with cerebral infarction following arterial occlusion * Treated for mechanical thrombectomy (whether performed or not) * Free, informed, and express consent of the patient or their relatives (emergency inclusion procedure) * For retrospective patients: thrombus already collected (according to the center's usual practice or for another research project). Exclusion Criteria: * Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman
Contact & Investigator
Jean-Philippe Désilles, MD
PRINCIPAL INVESTIGATOR
Fondation Ophtalmologique A. de Rothschild
Frequently Asked Questions
Who can join the NCT03268668 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03268668 currently recruiting?
Yes, NCT03268668 is actively recruiting participants. Contact the research team at ayavchitz@for.paris for enrollment information.
Where is the NCT03268668 trial being conducted?
This trial is being conducted at Bordeaux, France, Caen, France, Limoges, France, Nancy, France and 8 additional locations.
Who is sponsoring the NCT03268668 clinical trial?
NCT03268668 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild. The principal investigator is Jean-Philippe Désilles, MD at Fondation Ophtalmologique A. de Rothschild. The trial plans to enroll 1,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.